These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36123353)
1. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Huang BJ; Smith JL; Farrar JE; Wang YC; Umeda M; Ries RE; Leonti AR; Crowgey E; Furlan SN; Tarlock K; Armendariz M; Liu Y; Shaw TI; Wei L; Gerbing RB; Cooper TM; Gamis AS; Aplenc R; Kolb EA; Rubnitz J; Ma J; Klco JM; Ma X; Alonzo TA; Triche T; Meshinchi S Nat Commun; 2022 Sep; 13(1):5487. PubMed ID: 36123353 [TBL] [Abstract][Full Text] [Related]
2. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916 [TBL] [Abstract][Full Text] [Related]
3. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Ng SW; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD; Schuh AC; Yee KW; Bullinger L; Herold T; Görlich D; Büchner T; Hiddemann W; Berdel WE; Wörmann B; Cheok M; Preudhomme C; Dombret H; Metzeler K; Buske C; Löwenberg B; Valk PJ; Zandstra PW; Minden MD; Dick JE; Wang JC Nature; 2016 Dec; 540(7633):433-437. PubMed ID: 27926740 [TBL] [Abstract][Full Text] [Related]
4. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505 [TBL] [Abstract][Full Text] [Related]
5. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Ng SWK; Murphy T; King I; Zhang T; Mah M; Lu Z; Stickle N; Ibrahimova N; Arruda A; Mitchell A; Mai M; He R; Madala BS; Viswanatha DS; Dick JE; Chan S; Virtanen C; Minden MD; Mercer T; Stockley T; Wang JCY Blood Adv; 2022 Feb; 6(3):1064-1073. PubMed ID: 34872104 [TBL] [Abstract][Full Text] [Related]
6. CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia. Liu X; Liu X; Cai M; Luo A; He Y; Liu S; Zhang X; Yang X; Xu L; Jiang H Mol Cancer; 2021 Oct; 20(1):139. PubMed ID: 34702297 [TBL] [Abstract][Full Text] [Related]
7. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia. Verboon LJ; Obulkasim A; de Rooij JD; Katsman-Kuipers JE; Sonneveld E; Baruchel A; Trka J; Reinhardt D; Pieters R; Cloos J; Kaspers GJ; Klusmann JH; Zwaan CM; Fornerod M; van den Heuvel-Eibrink MM Oncotarget; 2016 Jul; 7(30):48412-48422. PubMed ID: 27351222 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Balgobind BV; Van den Heuvel-Eibrink MM; De Menezes RX; Reinhardt D; Hollink IH; Arentsen-Peters ST; van Wering ER; Kaspers GJ; Cloos J; de Bont ES; Cayuela JM; Baruchel A; Meyer C; Marschalek R; Trka J; Stary J; Beverloo HB; Pieters R; Zwaan CM; den Boer ML Haematologica; 2011 Feb; 96(2):221-30. PubMed ID: 20971820 [TBL] [Abstract][Full Text] [Related]
11. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328 [TBL] [Abstract][Full Text] [Related]
12. Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. Niu P; Yao B; Wei L; Zhu H; Fang C; Zhao Y Blood Cells Mol Dis; 2019 Jul; 77():43-50. PubMed ID: 30954792 [TBL] [Abstract][Full Text] [Related]
13. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML. Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055 [TBL] [Abstract][Full Text] [Related]
14. Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia. Thakral D; Singh VK; Gupta R; Jha N; Khan A; Kaur G; Rai S; Kumar V; Supriya M; Bakhshi S; Seth R Ann Hematol; 2023 Jan; 102(1):73-87. PubMed ID: 36527458 [TBL] [Abstract][Full Text] [Related]
15. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches. Thakral D; Gupta R; Khan A Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219 [TBL] [Abstract][Full Text] [Related]
16. Systematic computation with functional gene-sets among leukemic and hematopoietic stem cells reveals a favorable prognostic signature for acute myeloid leukemia. Yang XH; Li M; Wang B; Zhu W; Desgardin A; Onel K; de Jong J; Chen J; Chen L; Cunningham JM BMC Bioinformatics; 2015 Mar; 16():97. PubMed ID: 25887548 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia. Shi M; Xu G BMC Med Genomics; 2019 Jun; 12(1):90. PubMed ID: 31242922 [TBL] [Abstract][Full Text] [Related]
18. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J; Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Klein K; Beverloo HB; Zimmermann M; Raimondi SC; von Neuhoff C; de Haas V; van Weelderen R; Cloos J; Abrahamsson J; Bertrand Y; Dworzak M; Fynn A; Gibson B; Ha SY; Harrison CJ; Hasle H; Elitzur S; Leverger G; Maschan A; Razzouk B; Reinhardt D; Rizzari C; Smisek P; Creutzig U; Kaspers GJL Pediatr Blood Cancer; 2022 Jan; 69(1):e29341. PubMed ID: 34532968 [TBL] [Abstract][Full Text] [Related]
20. Network-based sub-network signatures unveil the potential for acute myeloid leukemia therapy. Shi M; Wu M; Pan P; Zhao R Mol Biosyst; 2014 Dec; 10(12):3290-7. PubMed ID: 25313005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]